Categories
Connect with us on LinkedIn
Practical ICH E6(R3) Oversight for Your Centralized Monitoring Strategy
Adopting ICH E6(R3) requires a shift from site-based monitoring to centralized oversight. For Phase 4 and RWE studies,...
Castor Professional Services: Expert Clinical Study Builds
Castor’s Professional Services team offers end-to-end support for clinical trial implementation, including EDC build, eCOA, and data management....
The real-time monitoring dilemma
Offline eCOA capability creates regulatory tension with EMA device-as-source requirements while eliminating real-time monitoring capabilities that drive 80-95%...
SCOPE 2026 Meet us at Booth #1612
February 2nd – 5th | Rosen Shingle Creek in Orlando, Florida
Join Castor at SCOPE US 2026, February 2-5 at Orlando's Rosen Shingle Creek. Discover how our "self-driving" clinical...
Executing Concurrent Decentralized RCTs and RWE at Scale
Discover how Sword Health used Castor to validate digital MSK care with scalable RCTs and real-world evidence strategies.
3-Week Database Builds That Withstood FDA Review
Castor’s EDC enabled Gameto’s 3-person team launch in 3 weeks, run 9 IVF studies on 4 continents, and...
Product Spotlight The Self-Driving Study with Castor Catalyst – On Demand
Join Castor CEO Derk Arts to explore Castor Catalyst, the agentic AI platform built with Google Cloud AI....
Is Your eCOA UAT Stuck in Time?
Modern clinical trials increasingly rely on complex, time-sensitive logic within eCOA systems, such as narrow compliance windows and...
The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives
The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing...
The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More
CNS trials fail not from technology limitations but organizational factors. Research reveals 55% of sites lack adequate eCOA...
Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials
Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays, staff turnover, and patient acuity...
Implications of Assessing Overall Survival in Oncology Studies
The FDA’s August 2025 draft guidance reshapes oncology clinical trials by requiring pre-specified overall survival (OS) analysis in...
The Patient Experience Paradox: eCOA Strategy Overhaul
Discover how the EMA’s new Patient Experience Data (PED) guidance and the EU HTA Regulation are reshaping evidence...
eConsent Readiness in 33 Countries: Your Global Compliance Roadmap
The definitive whitepaper, "eConsent Readiness in 33 Countries," provides an essential regulatory update for clinical operations, confirming that...
Castor Catalyst
Castor Catalyst revolutionizes real-world evidence generation by automating data extraction from EHR and claims data. Built with AI-driven...
From Months to Hours: MMC’s 5-Hour EDC Builds
Discover how a specialized CRO delivers first-in-human device studies at speed with Castor
Castor Catalyst: Launching Self-Driving Clinical Trials with Google Cloud AI
Castor has launched Castor Catalyst, an innovative AI-powered platform developed in collaboration with Google Cloud. Built on Google's...
Better Evidence Starts with Better Infrastructure
Join Castor at ISPOR Europe 2025 | November 9–12 | Glasgow, Scotland
Castor is attending ISPOR Europe 2025 in Glasgow to showcase smarter, faster approaches to real-world evidence. Join us...